These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9436636)

  • 21. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
    Izumi T; Muroi K; Hoshino Y; Komatsu N; Ohtsuki T; Yamada M; Tomizuka H; Hatake K; Furusawa S; Miura Y
    Gan To Kagaku Ryoho; 1996 May; 23(6):797-800. PubMed ID: 8645033
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients.
    Veneri D; Zanetti F; Franchini M; Krampera M; Pizzolo G
    Haematologica; 2002 Nov; 87(11):ELT43. PubMed ID: 12414364
    [No Abstract]   [Full Text] [Related]  

  • 24. A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma.
    Ezzat AA; Raja MA; Berry J; Abd El-Warith A; Khan BA; Rhydderch DC
    Am J Clin Oncol; 1997 Apr; 20(2):179-83. PubMed ID: 9124196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
    Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
    Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
    Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
    Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.
    Al-Ismail SA; Whittaker JA; Gough J
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1379-84. PubMed ID: 3315698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
    Silingardi V; Federico M; Cavanna L; Avanzini P; Gobbi PG; Lombardo M; Carotenuto M; Frassoldati A; Pieresca C; Vallisa D
    Leuk Lymphoma; 1995 Apr; 17(3-4):313-20. PubMed ID: 8580801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of cyclophosphamide (C), epirubicin (E), oncovin (O), prednisone (P), methotrexate (M) + leucovorin and bleomycin (B) (CEOP-MB) in intermediate and high grade non-Hodgkin lymphomas.
    Wils J; Smeets J
    J Chemother; 1991 Aug; 3(4):260-3. PubMed ID: 1723424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma.
    Liang R; Todd D; Chan TK
    Cancer Chemother Pharmacol; 1988; 22(2):169-71. PubMed ID: 2457455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
    Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide, epirubicin, vincristine and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
    Comella P; Abate G; Fiore M; Di Finizio G; Polverino W; Muto P; Zarrilli D
    Haematologica; 1988; 73(6):509-12. PubMed ID: 3148514
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma.
    Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D
    Ann Oncol; 1996 Dec; 7(10):1029-36. PubMed ID: 9037361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.
    Avilés A; Delgado S; Nambo MJ; Alatriste S; Díaz-Maqueo JC
    Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):799-803. PubMed ID: 7525515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
    Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
    Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.